Filing Flows › Comparisons › JAZZ vs BMRN
Jazz Pharmaceuticals vs BioMarin Pharmaceutical: JAZZ and BMRN compared
Jazz Pharmaceuticals is the larger company: $1.2B of revenue in its latest quarter (Q3 2026) against $1.0B for BioMarin Pharmaceutical (Q3 2026). BioMarin Pharmaceutical is growing faster (+32% against +10% a year earlier). BioMarin Pharmaceutical is more profitable, with an operating margin of -8.0% against -33.3%.
Where the money goes: JAZZ and BMRN
Jazz Pharmaceuticals (JAZZ) · Q3 2026
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
BioMarin Pharmaceutical (BMRN) · Q3 2026
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
| Jazz Pharmaceuticals (JAZZ) | BioMarin Pharmaceutical (BMRN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.2B | $1.0B |
| Revenue growth, Y/Y | +10% | +32% |
| Operating margin | -33.3% | -8.0% |
| Net earnings | −$483M | −$123M |
| Net margin | -38.9% | -12.0% |
| Operating cash flow | $506M | $188M |
| Free cash flow | $490M | $160M |
| Market value | $15.2B | $10.8B |
| P/E | 76.5× | — |
| Analysts’ mean target | $296.27 | $90.78 |
Where the revenue comes from
Jazz Pharmaceuticals
- Sleep: $514M (41%)
- Xywav: $482M (39%)
- Rylaze/Enrylaze: $106M (9%)
- Zepzelca: $104M (8%)
BioMarin Pharmaceutical
- Net product revenues: $1.0B (99%)
- Royalty and other revenues: $11.6M (1%)
Questions
Which is bigger, Jazz Pharmaceuticals or BioMarin Pharmaceutical?
Jazz Pharmaceuticals is the larger company: $1.2B of revenue in its latest quarter (Q3 2026) against $1.0B for BioMarin Pharmaceutical (Q3 2026).
Is Jazz Pharmaceuticals or BioMarin Pharmaceutical growing faster?
BioMarin Pharmaceutical is growing faster (+32% against +10% a year earlier).
Which is more profitable, Jazz Pharmaceuticals or BioMarin Pharmaceutical?
BioMarin Pharmaceutical is more profitable, with an operating margin of -8.0% against -33.3%.
More: Jazz Pharmaceuticals earnings · how Jazz Pharmaceuticals makes money · BioMarin Pharmaceutical earnings · how BioMarin Pharmaceutical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.